Literature DB >> 24616987

[Relationship between activated STAT3 protein and epithelial-mesenchymal transition in papillary thyroid carcinoma].

Zhuqing Zhang, Yan Bai, Ping Li, Junjun Zhao, Yanxia Wang, Lei Sun, Jianwu Tang.   

Abstract

OBJECTIVE: To investigate the expression of signal transducer and activator of transcription 3 (STAT3) and phosphorylated STAT3 (p-STAT3) protein in papillary thyroid carcinoma (PTC), and to explore the correlation and significance between the expression of STAT3, p-STAT3 and epithelial-mesenchymal transition (EMT).
METHOD: The expression of STATS3. p-STAT3, E-cadherin and Vimentin protein in 56 cases of PTC specimens and adjacent normal tissues specimens ware detected by immunohistochemistry. The correlation of the expression of STATS, p-STAT3, E-cadherin and Vimentin protein in PTC with clinicopathological characteristics was analyzed. RESULT: The positive rates of STAT3, p-STAT3 in PTC tissue were significantly higher than those in adjacent normal tissues specimens respectively (P < 0.01). The positive rates of E-cadherin in PTC tissues were remarkably lower, compared to adjacent normal tissues specimens (P < 0.01), however the positive rates of Vimentin in PTC tissues were remarkably higher, compared to adjacent normal tissues specimens (P < 0.01). The expression of STAT3, p-STAT3, E-cadherin and Vimentin protein were associated with lymph node metastasis and clinical stage (all P < 0.05). The expression of STAT3 and p-STAT3 was negatively correlated with E-cadherin expression (r = -0.494 and r = -0.364, P < 0.01, respectively), but positively with Vimentin expression (r = 0.533 and r = 0.377, P < 0.01, respectively) in PTC tissues.
CONCLUSION: PTC tissues have STAT3 protein activation and EMT phenotype, as were all correlated significantly with PTC invasion and metastasis. STAT3 signaling pathway activation might mediate EMT and then promote PTC invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24616987

Source DB:  PubMed          Journal:  Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 2096-7993


  7 in total

1.  Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer.

Authors:  L I Yan; L I Li; Qinghuai Li; Wang DI; Wei Shen; Linlei Zhang; Hao Guo
Journal:  Exp Ther Med       Date:  2015-04-07       Impact factor: 2.447

2.  SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  L-C Fan; C-W Shiau; W-T Tai; M-H Hung; P-Y Chu; F-S Hsieh; H Lin; H-C Yu; K-F Chen
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

3.  Platelet derived growth factor receptor alpha mediates nodal metastases in papillary thyroid cancer by driving the epithelial-mesenchymal transition.

Authors:  Esther Ekpe-Adewuyi; Ana Lopez-Campistrous; Xiaoyun Tang; David N Brindley; Todd P W McMullen
Journal:  Oncotarget       Date:  2016-12-13

4.  Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.

Authors:  Li-Ching Fan; Hao-Wei Teng; Chung-Wai Shiau; Wei-Tien Tai; Man-Hsin Hung; Shung-Haur Yang; Jeng-Kai Jiang; Kuen-Feng Chen
Journal:  Oncotarget       Date:  2016-09-27

5.  E-cadherin expression is associated with susceptibility and clinicopathological characteristics of thyroid cancer: A PRISMA-compliant meta-analysis.

Authors:  Changlin Zhou; Chunsheng Yang; Daoqun Chong
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

6.  Trefoil Factor 3 Inhibits Thyroid Cancer Cell Progression Related to IL-6/JAK/STAT3 Signaling Pathway.

Authors:  Yunchao Xin; Xiaoling Shang; Xiaoran Sun; Yachao Liu; Guogang Xu; Gang Xue
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-14       Impact factor: 2.629

7.  Role of STAT3 Expression in Thyroid Cancer: A Meta-Analysis and Systematic Review Based on the Chinese Population.

Authors:  Ya-Nan Liang; Zuwang Zhang; Ji Song; Fuwei Yang; Pan Yang
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-15       Impact factor: 2.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.